Recursion Prescribed drugs, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Digital Discussion board Transcript

Scott Schoenhaus
KeyBanc Capital Markets Inc., Analysis Division

3

Nice. Thanks, everybody, for becoming a member of. My identify is Scott Schoenhaus. I’m the well being care tech fairness analyst right here at KeyBanc. We’re a pleasure to have Ben Taylor, CFO of Recursion for a fireplace chat.

Ben, possibly it is useful to kind of introduce your self and the corporate for anybody that is new to your story. And you’ve got gone by quite a lot of adjustments during the last 12 to 24 months, too. So it is price highlighting your story to anybody that is new to it.

Ben Taylor
CFO & President of Recursion UK

Sure, in fact, blissful to. So my very own background, I used to be truly coming over from the Exscientia aspect of the merger. So I used to be the CFO and Chief Technique Officer over at Exscientia and had been there for somewhat over 4 years after we introduced the businesses collectively 18 months in the past. And earlier than that, I had truly run the day-to-day operations at an oncology biotech. So bought to see what it was like actually digging in and establishing scientific trials, going out to the scientific trial websites, working with the FDA.

And it was truly actually attention-grabbing as a result of it was what led me into the AI-based drug discovery. What I spotted is I and all of my colleagues round me and quite a lot of — so I have been in banking earlier than that. Loads of my shoppers had actually been guessing as a result of the information that you must make good choices is so sparse. And so we’ll take information that is popping out